Lupin’s Pithampur Unit-3 receives EIR from US FDA
Deepthi | Myequity news | Date : 10-12-2018 15:50:00 IST
Pharma major Lupin received the Establishment Inspection Report (EIR) for its Pithampur (Unit 3) facility. The inspection at the site was conducted between June 12, 2017 and June 16, 2017. This was a Pre-approval inspection for Albuterol Sulfate Inhalation product. Lupin’s Pithampur (Unit 3) facility manufactures Dermatological Products, Dry Product Inhalers and Metered Dose Inhalers. About Lupin Limited
Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, “The receipt of the EIR for our Pithampur Unit 3 is an encouraging development. This is a validation of our commitment to maintain the highest standards in quality and compliance across our facilities.”
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti- TB segment.